Overview
Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers
Status:
Completed
Completed
Trial end date:
2008-12-01
2008-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine the safety and efficacy of an investigational antiarrhythmic drug (ATI-2042) in the treatment of atrial fibrillation in patients with a dual chamber pacemaker.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
ARYx Therapeutics
Criteria
Inclusion Criteria:- Proven paroxysmal atrial fibrillation
- Pacemaker with appropriate AF diagnostics and recording capabilities
Exclusion Criteria:
- Known allergy to Amiodarone or previous treatment for severe Amiodarone toxicity
- Cardioversion within one month of screening
- Severe left ventricular dysfunction or CHF with NYHA Class III or above